ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 636,10
0,87%
Dow Jones
38 834,86
0,15%
DAX
18 194,14
0,70%
Brent Oil
84,645
-0,06%
Bitcoin
65 697,05
1,12%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Merus NV (MRUS)

  7. Merus NV (MRUS) Actualités

MRUS Merus NV

54,24
0,00 (0,00%)
Avant marché
Dernière mise à jour : 10:00:00
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Merus NV MRUS NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 54,24 10:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
54,24
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
17/6/202421:37EDGAR2Form 144 - Report of proposed sale of securities
12/6/202423:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/6/202420:30GLOBEMerus’ MCLA-129 Demonstrates Promising Single-Agent..
02/6/202418:30GLOBEMerus Presents Interim Data on MCLA-145 Monotherapy and in..
30/5/202423:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30/5/202403:30GLOBEMerus Announces Pricing of Upsized Public Offering of Common..
29/5/202414:00GLOBEMerus to Participate in a Fireside Chat at the Jefferies..
28/5/202422:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/5/202422:06EDGAR2Form 8-K - Current report
28/5/202422:01GLOBEMerus N.V. Announces Proposed Public Offering of Common..
28/5/202413:00GLOBEMerus’ Petosemtamab in Combination with Pembrolizumab..
23/5/202423:00GLOBEMerus Announces Publication of an Abstract on Petosemtamab..
13/5/202414:00GLOBEPetosemtamab granted Breakthrough Therapy Designation by the..
10/5/202422:33EDGAR2Form 8-K/A - Current report: [Amend]
09/5/202422:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/5/202422:15GLOBEMerus Announces Financial Results for the First Quarter 2024..
08/5/202414:01EDGAR2Form 8-K - Current report
06/5/202422:05GLOBEMerus Announces U.S. FDA Acceptance and Priority Review of..
08/4/202418:00GLOBEMerus Presents Preclinical Data Demonstrating Efficacy of..
03/4/202414:00GLOBEMerus to Participate in a Fireside Chat at the 23rd Annual..
06/3/202414:15EDGAR2Form 8-K - Current report
06/3/202414:00BWGilead and Merus Announce Collaboration to Discover Novel..
05/3/202422:30GLOBEMerus Announces Publication of an Abstract for Presentation..
04/3/202414:00GLOBEMerus to Participate in a Fireside Chat at the Leerink..
28/2/202422:55EDGAR2Form S-3ASR - Automatic shelf registration statement of..
28/2/202422:15GLOBEMerus Announces Financial Results for the Fourth Quarter and..
14/2/202422:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31/1/202414:00GLOBEMerus to Participate in Upcoming Investor Conferences
20/12/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/12/202323:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/12/202301:29EDGAR2Form 144 - Report of proposed sale of securities
12/12/202322:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/12/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/12/202302:40GLOBEMerus Presents Interim Data on MCLA-129 at ESMO Asia..
01/12/202316:47EDGAR2Form 144 - Report of proposed sale of securities
26/11/202317:05GLOBEMerus Announces Publication of Abstracts on MCLA-129 for..
02/11/202321:12GLOBEMerus Announces Financial Results for the Third Quarter 2023..
02/11/202321:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202313:00GLOBEMerus to Participate in Upcoming Investor Conferences
23/10/202313:30GLOBEMerus’ Zeno Interim Data Continues to Demonstrate Robust and..
16/10/202301:58GLOBEMerus Announces Business Update Conference Call
11/10/202322:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/10/202322:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Dernières Valeurs Consultées

NASDAQ
MRUS
Merus NV
BIT
P1XZM5
NLBNPIT1XZM5 20240621 1....
USOTC
NKLXF
Nickelex Resource (QB)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés